Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the filing of a divisional patent application for its Trap & Target (T&T) platform technology with the Israel Patent Office.

New API discovery and protection capabilities are aimed at helping customers secure distributed applications that span on-premises and cloud locations. F5 is reinforcing application security with a ...

FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy ...